Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets

Karl T. Weber, Ivan C. Gerling, Mohammad F. Kiani, Ramareddy V. Guntaka, Yao Sun, Robert A. Ahokas, Arnold E. Postlethwaite, Kenneth J. Warrington

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Heart failure is a major health problem of epidemic proportions. Irrespective of its etiologic origins, a dysfunction of this normally efficient muscular pump is associated with systemic consequences, a progressive downhill clinical course and poor prognosis. Ventricular dysfunction is ultimately accompanied by neurohormonal system activation that accounts for: the congestive heart failure syndrome; an induction of oxi/nitrosative stress; adverse vascular remodeling; and activation of the immune system that contributes to a wasting syndrome known as cardiac cachexia. Circulating effector hormones of the renin-angiotensin-aldosterone system are an integral feature of this neurohormonal activation; they have systemic consequences. Insights into the pathophysiology of heart failure will identify improved methods of prevention, including biomarkers to aid in its detection and identification of risk, and to the development of specific drug targets. Herein we address one aspect of the neurohormonal profile of heart failure, namely that related to aldosteronism. Our focus is directed at the link between aldosteronism and its adverse influence on coronary vasculature structure, a proinflammatory/fibrogenic cardiac phenotype, which is based on an immunostimulatory state that includes activated peripheral blood mononuclear cells.

Original languageEnglish (US)
Pages (from-to)505-516
Number of pages12
JournalCurrent drug targets
Issue number6
StatePublished - Aug 2003

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomakers and potential drug targets'. Together they form a unique fingerprint.

Cite this